INVENTIVA SA (IVA.PA) Stock Overview
Europe - EPA:IVA - FR0013233012 - Common Stock
IVA.PA Key Statistics, Chart & Performance
The current stock price of IVA.PA is 4.58 EUR. In the past month the price increased by 18.04%. In the past year, price increased by 154.44%.
IVA.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.12 | 334.23B | ||
| AMG.DE | AMGEN INC | 13.04 | 129.50B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.74 | 119.81B | ||
| 1VRTX.MI | VERTEX PHARMACEUTICALS INC | 23.36 | 85.81B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 22.91 | 84.19B | ||
| 1AE.DE | ARGENX SE | 85.58 | 38.29B | ||
| ARGX.BR | ARGENX SE | 85.53 | 38.26B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.75B | ||
| 1BIIB.MI | BIOGEN INC | 9.34 | 18.55B | ||
| IDP.DE | BIOGEN INC | 8.96 | 17.79B | ||
| 1EXEL.MI | EXELIXIS INC | 18.85 | 8.93B | ||
| 0QF.DE | MODERNA INC | N/A | 8.33B |
Related stock screener links
About IVA.PA
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 109 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
INVENTIVA SA
50 rue de Dijon, Daix
Daix OCCITANIE FR
Employees: 116
Phone: 33380447500
INVENTIVA SA / IVA.PA FAQ
What is the stock price of INVENTIVA SA today?
The current stock price of IVA.PA is 4.58 EUR. The price increased by 1.89% in the last trading session.
What is the ticker symbol for INVENTIVA SA stock?
The exchange symbol of INVENTIVA SA is IVA and it is listed on the Euronext Paris - Matif exchange.
On which exchange is IVA.PA stock listed?
IVA.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for INVENTIVA SA stock?
13 analysts have analysed IVA.PA and the average price target is 10.77 EUR. This implies a price increase of 135.14% is expected in the next year compared to the current price of 4.58. Check the INVENTIVA SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INVENTIVA SA worth?
INVENTIVA SA (IVA.PA) has a market capitalization of 637.00M EUR. This makes IVA.PA a Small Cap stock.
How many employees does INVENTIVA SA have?
INVENTIVA SA (IVA.PA) currently has 116 employees.
What are the support and resistance levels for INVENTIVA SA (IVA.PA) stock?
INVENTIVA SA (IVA.PA) has a support level at 4.57 and a resistance level at 4.62. Check the full technical report for a detailed analysis of IVA.PA support and resistance levels.
Is INVENTIVA SA (IVA.PA) expected to grow?
The Revenue of INVENTIVA SA (IVA.PA) is expected to grow by 221.09% in the next year. Check the estimates tab for more information on the IVA.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INVENTIVA SA (IVA.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IVA.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IVA.PA, evaluating the profitability, health, valuation and growth aspects
- INVENTIVA SA (IVA.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INVENTIVA SA (IVA.PA) Sales and EPS estimates to see what analysts future expectations are.
- INVENTIVA SA (IVA.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INVENTIVA SA (IVA.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- INVENTIVA SA (IVA.PA) Stock Chart to make your own analysis
- INVENTIVA SA (IVA.PA) Latest news and press-releases to stay up to date.
Does INVENTIVA SA (IVA.PA) stock pay dividends?
IVA.PA does not pay a dividend.
When does INVENTIVA SA (IVA.PA) report earnings?
INVENTIVA SA (IVA.PA) will report earnings on 2025-09-25, before the market open.
What is the Price/Earnings (PE) ratio of INVENTIVA SA (IVA.PA)?
INVENTIVA SA (IVA.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.94).
IVA.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IVA.PA. When comparing the yearly performance of all stocks, IVA.PA is one of the better performing stocks in the market, outperforming 98.51% of all stocks.
IVA.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IVA.PA. Both the profitability and financial health of IVA.PA have multiple concerns.
IVA.PA Financial Highlights
Over the last trailing twelve months IVA.PA reported a non-GAAP Earnings per Share(EPS) of -2.94. The EPS decreased by -20.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.84% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IVA.PA Forecast & Estimates
13 analysts have analysed IVA.PA and the average price target is 10.77 EUR. This implies a price increase of 135.14% is expected in the next year compared to the current price of 4.58.
For the next year, analysts expect an EPS growth of 63.99% and a revenue growth 221.09% for IVA.PA